Savior Lifetec Corp. (4167) AI Stock Analysis

Savior Lifetec Corp.

(TPEx:4167)

Select Model

Rating:60Neutral

Price Target:TWD 19.50▲(2.63% Upside)

Action:initiatedcoverage

Date:11/09/26

Savior Lifetec earns a moderate score. The dominant driver is its financial profile: an exceptionally conservative, near debt-free balance sheet and a sharp gross margin recovery to 35.2% are offset by stagnant revenue, weakening EBITDA, and the key red flag of negative operating and free cash flow despite record reported earnings — suggesting the profit surge was driven by non-operating items rather than the core business. Valuation provides support, with a 6.47 P/E, a 4.37% dividend yield and low beta, though the cheap multiple is flattered by that low-quality earnings base. Technicals are the weakest element, with the price below all major moving averages and a negative MACD, although deeply oversold RSI and Stochastic readings hint at scope for a near-term rebound. Investors should look for sustained revenue growth and normalized cash conversion before the earnings improvement can be fully credited.

Positive Factors

Low Financial LeverageVery low leverage gives Savior Lifetec meaningful financial flexibility and reduces interest and refinancing pressure. The stronger equity base can help the company absorb earnings volatility, fund operations, and pursue development without relying heavily on additional borrowing.

Negative Factors

Negative 2025 Cash FlowThe reversal to negative operating and free cash flow creates a material quality-of-earnings concern because reported net income was high while cash generation weakened. If this persists, internal funding capacity could decline and the company may face greater execution or financing pressure.

Savior Lifetec Corp. (4167) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 6.38B
Dividend Yield: 4.23%
Average Volume (3M): 1.57M
Price to Earnings (P/E): 6.3
Beta (1Y): 0.47
Revenue Growth: -0.05%
EPS Growth: 64.82%
Country: TW
Employees: 375
Sector: General
Sector Strength: 55
Industry: Biotechnology

Savior Lifetec Corp. Business Overview & Revenue Model

Company Description

Savior Lifetec Corporation, a specialty injectable company, develops, produces, and supplies sterile active pharmaceutical ingredients and finished dosage formulations. The company provides various carbapenem generic drugs and injections, such as pal...

Savior Lifetec Corp. Financial Statement Overview

Summary

A mixed profile. The balance sheet is a genuine strength (score 82): debt cut to NT$183 million, debt-to-equity of just 0.05, and roughly 90% of assets funded by equity, giving strong resilience. The income statement (62) shows an impressive gross margin recovery from 10.3% to 35.2% and a jump in net income to NT$533.6 million (14.1% ROE), but revenue remains well below prior-cycle levels and EBITDA actually fell, indicating the profit surge came largely from non-operating items. Cash flow is the clear weak link (35): operating cash flow swung to negative NT$21.0 million and free cash flow to negative NT$164.3 million despite record reported profits, confirming poor earnings-to-cash conversion and recurring volatility.

Income Statement

62Positive

Balance Sheet

82Very Positive

Cash Flow

35Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.12B	1.20B	1.22B	1.05B	1.27B	1.74B
Gross Profit	370.87M	423.41M	346.76M	220.95M	130.99M	307.87M
EBITDA	-71.06M	274.34M	314.02M	219.60M	260.73M	263.33M
Net Income	1.03B	533.64M	182.38M	30.03M	20.62M	-4.76M
Balance Sheet
Total Assets	5.16B	4.18B	4.38B	3.82B	4.41B	4.54B
Cash, Cash Equivalents and Short-Term Investments	2.72B	1.61B	2.12B	1.34B	1.65B	507.13M
Total Debt	290.91M	183.25M	177.78M	270.38M	803.27M	951.25M
Total Liabilities	768.96M	403.30M	860.02M	457.96M	1.04B	1.23B
Stockholders Equity	4.39B	3.78B	3.51B	3.35B	3.35B	3.31B
Cash Flow
Free Cash Flow	14.44M	-164.28M	399.92M	370.68M	547.60M	-263.94M
Operating Cash Flow	124.46M	-21.04M	518.38M	387.95M	581.77M	-168.34M
Investing Cash Flow	326.10M	-233.06M	-203.49M	181.19M	20.29M	18.53M
Financing Cash Flow	-38.35M	-280.56M	-39.74M	-572.22M	-7.48M	-41.37M

Savior Lifetec Corp. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:4167 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:4166	70Outperform	TWD 5.47B	22.88	―	―	―	―
TW:1734	64Neutral	TWD 6.07B	16.18	―	3.13%	2.44%	-3.96%
TW:4167	60Neutral	TWD 6.30B	6.34	―	4.23%	-0.05%	64.82%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:4157	52Neutral	TWD 5.78B	36.61	―	―	530.40%	―
TW:4119	48Neutral	TWD 5.85B	96.18	―	1.53%	-18.83%	-87.54%

* General Sector Average

Performance Comparison

TW:4167 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:4167	Savior Lifetec Corp.	19.00	2.23	13.28%
TW:1734	Sinphar Pharmaceutical Co. Ltd.	30.10	1.71	6.02%
TW:4119	SCI Pharmtech Corp.	48.95	-0.16	-0.33%
TW:4157	TaiGen Biopharmaceuticals Holdings Limited	8.12	-1.40	-14.71%
TW:4166	Orient Pharma Co., Ltd.	22.50	-2.10	-8.54%
TW:7754	Annji Pharmaceutical Co., Ltd.	61.20	16.55	37.08%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

Savior Lifetec Corp. AI Stock Analysis